Aim immunotech announces positive top-line, protocol-planned interim report data from the study of ampligen combined with pembrolizumab for the treatment of recurrent ovarian cancer

Ocala, fla., april 10, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim”) today announced top-line interim data indicating that combining ampligen (rintatolimod) with keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a powerful synergistic effect, leading the investigator to conclude that the combination therapy could be far more effective than pembrolizumab alone as a therapy for the disease.
AIM Ratings Summary
AIM Quant Ranking